A Novel Domain‐Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone
暂无分享,去创建一个
Igor Fijalkowski | Geert Mortier | G. Mortier | F. Ramos | A. Fortuna | Igor Fijałkowski | W. Van Hul | Eveline Boudin | Wim Van Hul | Ana Maria Fortuna | Feliciano J Ramos | Viviane Van Hoof | Ellen Geets | Ellen Steenackers | V. Van Hoof | E. Steenackers | E. Boudin | E. Geets
[1] Cesar Libanati,et al. Romosozumab in postmenopausal women with low bone mineral density , 2014, The New England journal of medicine.
[2] F. Natt,et al. Control of the SOST Bone Enhancer by PTH Using MEF2 Transcription Factors , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] R. Stevenson,et al. Truncating mutations in LRP4 lead to a prenatal lethal form of Cenani–Lenz syndrome , 2014, American journal of medical genetics. Part A.
[4] Minrong Ai,et al. The Binding Between Sclerostin and LRP5 is Altered by DKK1 and by High-Bone Mass LRP5 Mutations , 2008, Calcified Tissue International.
[5] K. Lindpaintner,et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease , 2002, Journal of medical genetics.
[6] B. Schoser,et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis , 2012, Journal of Neurology.
[7] D. Galas,et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. , 2001, American journal of human genetics.
[8] K. Anderson,et al. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction , 2006, Development.
[9] C. Stratakis,et al. Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21. , 1999, American journal of human genetics.
[10] Sabine Geisse,et al. Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function* , 2011, The Journal of Biological Chemistry.
[11] G. Damante,et al. Identification of the first deletion in the LRP5 gene in a patient with Autosomal Dominant Osteopetrosis type I , 2011, Bone.
[12] L. Mei,et al. LRP4 Is Critical for Neuromuscular Junction Maintenance , 2014, The Journal of Neuroscience.
[13] P. Beighton,et al. Sclerosteosis — An autosomal recessive disorder , 1977, Clinical genetics.
[14] D. Galas,et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. , 2002, American journal of medical genetics.
[15] T. Huber,et al. Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels , 2014, Proceedings of the National Academy of Sciences.
[16] M Dioszegi,et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.
[17] Y. Yamanashi,et al. Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis , 2011, Annals of neurology.
[18] R. Lewis,et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. , 2012, Archives of neurology.
[19] W. Hul,et al. Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21. , 1998, American journal of human genetics.
[20] M. Hoylaerts,et al. Improved agarose electrophoretic method for separating alkaline phosphatase isoenzymes in serum. , 1988, Clinical chemistry.
[21] A. Masuda,et al. LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner. , 2014, Human molecular genetics.
[22] L. Mei,et al. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption , 2015, Proceedings of the National Academy of Sciences.
[23] A. Truswell. Osteopetrosis with syndactyly; a morphological variant of Albers-Schönberg's disease. , 1958, The Journal of bone and joint surgery. British volume.
[24] D. Ovcharenko,et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. , 2005, Genome research.
[25] E. Posvar,et al. Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] P. Scambler,et al. LRP4 mutations alter Wnt/beta-catenin signaling and cause limb and kidney malformations in Cenani-Lenz syndrome. , 2010, American journal of human genetics.
[27] E. Bakker,et al. Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[28] A. Chiang,et al. Single‐ and Multiple‐Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[29] W. Lenz,et al. [Total syndactylia and total radioulnar synostosis in 2 brothers. A contribution on the genetics of syndactylia]. , 1967, Zeitschrift fur Kinderheilkunde.
[30] J. Herz,et al. Lrp4, a Novel Receptor for Dickkopf 1 and Sclerostin, Is Expressed by Osteoblasts and Regulates Bone Growth and Turnover In Vivo , 2009, PloS one.
[31] Xi He,et al. SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor* , 2005, Journal of Biological Chemistry.
[32] R. Hammer,et al. Abnormal development of the apical ectodermal ridge and polysyndactyly in Megf7-deficient mice. , 2005, Human molecular genetics.